(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Every year approximately 750,000 Americans have a new or recurrent stroke. The second most common cause of death worldwide, stroke is also the leading cause of serious long-term disability; 15% to 30% of stroke survivors experience permanent disability. According to the American Heart Association, the mean lifetime cost resulting from an ischemic stroke is estimated at $140,000 per patient. Other than tissue plasminogen activator (tPA), which must be administered 3 hours after stroke, there are no FDA approved medicines for this indication.
About D-Pharm Ltd.
D-Pharm (http://www.dpharm.com) is clinical stage biopharmaceutical
company pioneering the development of lipid-like therapeutics and has
generated a rich pipeline of patent protected proprietary products.
D-Pharm's pipeline includes advanced clinical stage products, DP-b99 and
DP-VPA, a novel drug for treatment of epilepsy, bipolar disorder and
migraine prophylaxis, currently in Phase II development. DP-460 is in
preclinical development intended as an oral, disease-modifying therapy for
Alzheimer's disease. Other mimics of bioactive lipids, LipidoMimetix, are
at an earlier developmental stage, for cancer.
For further information please contact:
Tami Horovitz, PhD.
|SOURCE D-Pharm Ltd|
Copyright©2008 PR Newswire.
All rights reserved